Limitations of Current Biomarkers in Assessing Post-Pregnancy Heart Failure Risk
New research questions the effectiveness of traditional biomarkers like NT-proBNP for predicting heart failure in women after complicated pregnancies, emphasizing the need for new screening methods.
Recent research indicates that the biomarkers traditionally used to predict heart failure risk may not be effective for women following complicated pregnancies, such as those affected by hypertension or diabetes. A study published in JAMA Cardiology analyzed over 4,000 pregnancies across various medical centers, focusing on NT-proBNP, a common biomarker for heart failure. While approximately 1 in 17 women exhibited elevated levels of NT-proBNP years after childbirth — suggesting cardiac stress — pregnancies with conditions like preeclampsia, hypertension, or gestational diabetes did not show a corresponding increase in this biomarker. Contrary to expectations, women with these pregnancy complications tended to have lower levels of NT-proBNP, which challenges its reliability in postpartum cardiovascular screening.
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Reevaluating Low-Grade Prostate Cancers: Higher Risks Than Biopsy Results Indicate
New research indicates that some low-grade prostate cancers may pose higher risks than biopsy results suggest, urging a more comprehensive approach to diagnosis and treatment planning.
Advances in Psoriasis Treatment Offer New Hope for Patients
Modern advancements in psoriasis treatments have transformed management of this inflammatory skin condition, offering hope for clearer skin and improved quality of life for millions worldwide.
150 Minutes of Exercise Weekly May Reverse Prediabetes
Engaging in just 150 minutes of exercise weekly can help reverse prediabetes and reduce the risk of developing type 2 diabetes, according to new research.
Five-Year Follow-Up Shows Enzalutamide Extends Survival in Men with Advanced Prostate Cancer
A five-year follow-up of the ARCHES study reveals that combining enzalutamide with hormone therapy significantly extends survival in men with metastatic hormone-sensitive prostate cancer, offering new hope for improved treatment outcomes.